Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances: Proceedings of the Second International Conference on Malignant Lymphomas, Lugano, Switzerland, June 13 – 16, 1984

Front Matter....Pages I-XV
Front Matter....Pages 1-1
The cell of origin of Hodgkin’s disease....Pages 3-6
Hodgkin’s disease: Further information derived from cell lines....Pages 7-15
Origin and biologic function of Reed-Sternberg cells....Pages 17-24
Immunologic phenotypes of non-Hodgkin’s lymphomas: Correlation with morphology and function....Pages 25-36
Non-Hodgkin’s lymphoma with multilobated nuclei is not a distinct pathologic entity....Pages 37-44
Burkitt’s lymphoma: Multiparametric analysis of 55 cell lines with special reference to morphometry....Pages 45-55
Regulation of T-cell colony formation in the absence of added growth factors, in patients with T-cell malignancies....Pages 57-69
Front Matter....Pages 71-71
Banded chromosome abnormalities in non-Hodgkin’s lymphoma. Correlations with morphology, immunologic phenotype and clinical course....Pages 73-80
Chromosomal aberrations in leukemic low-grade malignant B-cell lymphoproliferative neoplasias....Pages 81-87
Chromosome abnormalities in Burkitt lymphoma and Burkitt-type acute lymphoblastic leukemia....Pages 89-99
DNA content and proliferation in non-Hodgkin’s lymphoma: Flow cytofluorometric DNA analysis in relation to the Kiel classification....Pages 101-114
Oncogenes in human neoplasms....Pages 115-122
Stage specific transforming genes in lymphoid neoplasms....Pages 123-127
Front Matter....Pages 129-129
DNA synthetic and degradative pathways in malignant lymphomas....Pages 131-139
Enzymes involved in adenosine metabolism in normal or leukemic lymphocytes....Pages 141-149
Purine metabolism in normal and pathologic lymphoid cell differentiation....Pages 151-161
Purine degradative enzymes in the malignant cells of patients with B-cell leukemia....Pages 163-170
Lymphocyte uroporphyrinogen synthase activity as a diagnostic test in lymphoproliferative disorders — preliminary results....Pages 171-174
Enzymatic and ultrastructural properties of the plasma membrane in human leukemias, in non-Hodgkin’s lymphomas and in human lymphoblastoid cells....Pages 175-183
Front Matter....Pages 185-185
Prognostic significance of cytologic subdivision in nodular sclerosing Hodgkin’s disease: An analysis of 1156 patients....Pages 187-200
Front Matter....Pages 185-185
Comparison of the Working Formulation of non-Hodgkin’s lymphoma with the Rappaport, the Kiel, and the Lukes-Collins Classifications. Correlations and prognostic value....Pages 201-213
Bone marrow and blood involvement by non-Hodgkin’s lymphoma: Clinicopathologic features and prognostic significance in relationship to the Working Formulation....Pages 215-224
Clonal blood B-cell excess in relation to prognosis in untreated non-leukemic patients With non-Hodgkin’s lymphoma (NHL)....Pages 225-232
Patterns of survival in advanced non-Hodgkin’s lymphoma....Pages 233-241
Front Matter....Pages 243-243
Acquired Immune Deficiency Syndrome (AIDS): Basic findings....Pages 245-250
Malignant lymphoma in homosexual men : Relationship to Acquired Immune Deficiency Syndrome (AIDS)....Pages 251-260
Unusual presentations of non-Hodgkin’s lymphomas in homosexual males....Pages 261-267
Immunoproliferative small intestinal disease....Pages 269-277
Front Matter....Pages 279-279
The current status of the Stanford randomized clinical trials of the management of Hodgkin’s disease....Pages 281-292
The current status of NCI trials in Hodgkin’s disease....Pages 293-298
Current status of the Milan trials for Hodgkin’s disease in adults....Pages 299-307
Indications for combined modality therapy in patients with Hodgkin’s disease....Pages 309-316
Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Results 14 years later....Pages 317-327
Treatment of early stage Hodgkin’s disease: A randomized trial of radiotherapy plus chemotherapy versus chemotherapy alone....Pages 329-336
Randomized study of chemotherapy alone vs. chemotherapy plus radiotherapy in Clinical Stages IA-IIA Hodgkin’s disease....Pages 337-343
Chemotherapy alone versus combined modality therapy for Stage III Hodgkin’s disease: A five-year follow-up of a Southwest Oncology Group study (SWOG-7518) USA....Pages 345-351
Chemotherapy plus radiotherapy in Clinical Stage IA to IIIB Hodgkin’s disease. Results of the H 77 trial (1977–1980)....Pages 353-361
Surgical restaging after 3 or 6 courses of MOPP chemotherapy in Hodgkin’s disease....Pages 363-369
Staging laparotomy with splenectomy in Stage I and II Hodgkin’s disease. No therapeutic benefit....Pages 371-377
Comparison of initial splectomy and spleen irradiation in Clinical Stages I and II Hodgkin’s disease....Pages 379-384
Front Matter....Pages 279-279
Prognostic groups for management of clinically localized Hodgkin’s disease....Pages 385-391
Management of localized, infradiaphragmatic Hodgkin’s disease: Experience of a rare clinical presentation at St. Bartholomew’s Hospital....Pages 393-401
Chemotherapy (MVPP) for Stage IIIB/IV Hodgkin’s disease with an assessment of prognostic factors....Pages 403-408
Incidence of liver involvement and correlation of biopsy results with Ann Arbor clinical criteria and response to chemotherapy in advanced Hodgkin’s disease: A Southwest Oncology Group study....Pages 409-416
Second cancers after treatment in two successive cohorts of patients with early stages of Hodgkin’s disease....Pages 417-428
Late complications of cytotoxic chemotherapy given for advanced Hodgkin’s disease....Pages 429-437
Front Matter....Pages 439-439
Overview on current strategy of the treatment of non-Hodgkin’s lymphomas....Pages 441-454
The low grade non-Hodgkin’s lymphomas: Current approaches to therapy....Pages 455-464
Treatment of diffuse large cell non-Hodgkin’s lymphomas....Pages 465-469
The use of chemotherapy for localized large cell lymphoma. Results from the University of Arizona....Pages 471-474
A randomized comparison of two chemotherapy regimes: BACOP vs COPP in the treatment of diffuse histiocytic and mixed lymphoma....Pages 475-483
Results of ifosfamide-Etoposide combinations for patients with recurrent or refractory aggressive lymphoma....Pages 485-492
New agents for Hodgkin’s and non-Hodgkin’s lymphomas....Pages 493-511
Autologous stem cell transplant for poor prognosis lymphoma....Pages 513-520
 In vitro purging with 4-hydroperoxycyclophosphamide and its effects on the hematopoietic and stromal elements of human bone marrow....Pages 521-528
Treatment of refractory non-Hodgkin’s lymphoma with intensive chemo-radiotherapy and autologous bone marrow transplantation....Pages 529-536
Transplantation with anti-B 1 monoclonal antibody and complement treated autologous bone marrow for relapsed B-cell non-Hodgkin’s lymphoma....Pages 537-547
The immunobiology of B-cell lymphoma. Studies with anti-idiotype antibodies....Pages 549-556
Therapeutic use of monoclonal anti-idiotype antibodies against B-cell lymphoma....Pages 557-568
Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1)....Pages 569-577
Front Matter....Pages 439-439
Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody....Pages 579-590
Clinical interferon (IFN) studies in leukemia and lymphoma....Pages 591-600
Front Matter....Pages 601-601
Current status of the curability of children with Hodgkin’s disease: An assessment of the risk: benefit ratio of modern therapy....Pages 603-609
Treatment of childhood Stages I and II Hodgkin’s disease without radiotherapy....Pages 611-615
Combined modality treatment with reduced chemotherapy and radiotherapy, and selective splenectomy, in children with Hodgkin’s disease....Pages 617-626
Strategies for management of childhood non-Hodgkin’s lymphomas based upon stage and immunopathologic subtype Rationale and current results....Pages 627-632
BFM trials for childhood non-Hodgkin’s lymphomas....Pages 633-642
Characteristics and results of treatment of non-Hodgkin’s lymphoma in young people — Experience of the Pediatric Branch, NCI, USA....Pages 643-653
Back Matter....Pages 655-669